A Randomized, Multicenter, Phase II Study Comparing the Combination of Pazopanib and Lapatinib Versus Lapatinib Monotherapy in Patients With ErbB2 Over-Expressing Inflammatory Breast Cancer.
Phase of Trial: Phase II
Latest Information Update: 21 Aug 2014
At a glance
- Drugs Pazopanib (Primary) ; Lapatinib
- Indications Advanced breast cancer
- Focus Registrational; Therapeutic Use
- Sponsors GlaxoSmithKline
- 17 Jul 2012 Actual number of patients changed from 184 to 163, as reported by ClinicalTrials.gov.
- 05 Jun 2012 Results presented at the 48th Annual Meeting of the American Society of Clinical Oncology.
- 06 Apr 2012 Actual patient number 184 added as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History